Search

Experienced physician executive Dr. Thomas Graf named interim Today, the Renown Health Board of Trustees, led by Adam Kramer, announced that Dr. Tony Slonim’s tenure has ended as president and CEO of Renown Health. Thomas R. Graf, M.D., FAAFP will now serve as interim Chief Executive Officer. Dr. Graf will assume the title and authority of CEO in addition to his current role as Chief Clinical and Quality Officer at Renown, and Senior Associate Dean for Clinical Affairs for University of Nevada, Reno School of Medicine. Sy Johnson, MBA, Renown’s current Chief Operating Officer has been promoted to interim President and COO. Following the completion of a thorough investigation of concerns raised to the Board of Directors, the Board determined that Renown Health, its patients and staff required new leadership. Accordingly, Dr. Slonim has been terminated with cause as CEO of Renown Health. Mr. Kramer announced the transition today by writing, “a new direction and leadership is needed given the critical work ahead. I have complete faith in Dr. Tom Graf and Sy Johnson, and their senior leadership teams, who already oversee health care system operations, and will help ensure a smooth transition.” Dr. Graf will work in collaboration with Sy Johnson, MBA, interim President and Chief Operations Officer and an experienced team of healthcare executives, to lead Renown to achieve its strategic and operational goals. Kramer added, “For more than 160 years, Renown has provided health care that is affordable, accessible and of the highest quality for our community. This commitment continues as our 7,000 health care heroes continue doing what is most important, and what we do best - caring for our community.” Dr. Graf will continue to fuel Renown’s transformation to a value-based care organization, help advance technologies to enhance the patient experience, and collaborate with providers in Renown Medical Group, acute care hospitals, and through the Western Clinical Alliance clinically integrated network, accountable care organization and affiliation with UNR Med. Graf is a highly accomplished physician executive who has led health care and insurance organizations as well as a national consulting firm. A family medicine physician, researcher and academic, Dr. Graf has focused on driving quality improvement to lower the total cost of care. He has developed and published on care models that have delivered measurably better results for quality, cost, and experience in a variety of venues. He has practiced in an integrated delivery system, with over a decade at Geisinger (PA), as well as clinically integrated networks and accountable care organizations. He also has worked with a number of academic medical centers through his consulting work with The Chartis Group. Dr. Graf adds, “My goal is to produce greater value for the patient by delivering care that is of highest clinical quality. Renown has a national reputation for delivering excellent care using approaches that are creative, innovative and maximize technology, and I look forward to engaging physicians and administrators in an agenda that supports this vision. I am grateful for the opportunity to contribute to the great progress that Renown Health is making in becoming the best place to practice medicine and to receive care. I am excited to join this journey of transformation to value- based care, and to serve patients, clinicians and our community.” Sy Johnson has led Renown Health hospital and network operations for almost seven years, most recently as Chief Of Staff / Chief Operating Officer and formerly as Renown’s Executive Vice President and Chief Operating Officer. Prior to joining Renown, Mr. Johnson served as CEO, Senior Vice President and as Chief Financial Officer for Peace Health in Vancouver, Washington, and in senior management with Arthur Andersen & Co and KPMG. About Renown Health Renown Health is the region’s largest, locally governed, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. With a diverse workforce of more than 7,000 employees, Renown has fostered a longstanding culture of excellence, determination and innovation. The organization comprises a trauma center, two acute care hospitals, a children’s hospital, a rehabilitation hospital, a medical group and urgent care network, and the region’s largest, locally owned not-for-profit insurance company, Hometown Health. Renown is currently enrolling participants in the world’s largest community-based genetic population health study, the Healthy Nevada Project®. For more information, visit renown.org.

Read More About Renown Health Board Announces CEO Transition

Healthcare physician CEO with 20 years of experience to lead northern NV’s largest health system on Nov. 14, 2022 Renown Health has selected Brian Erling, MD, MBA, as the health system’s next CEO and president, effective November 14, 2022. Dr. Erling is a seasoned healthcare executive with over 20 years of experience leading teams in diverse healthcare settings, including locally governed, not-for-profit hospitals and integrated health systems; physician practices; publicly traded healthcare companies; and private equity-backed healthcare ventures Dr. Erling is a former healthcare executive with Centura Health in Denver having served since 2016 in positions of increasing and major responsibility, including Chief Medical Officer, Senior Vice President & Chief Clinical Officer and most recently as President & CEO of Penrose-St. Francis Health Services which represents the Colorado Springs market for Centura Health and includes Penrose Hospital, St. Francis Hospital, and St. Francis Hospital-Interquest slated to open in July 2023. During his tenure, he served as Senior Vice President and Chief Clinical Officer, responsible for providing clinical leadership to 17 hospitals and 21,000 caregivers. A highly experienced emergency medicine physician, Dr. Erling has long been a leader in quality improvement and is a Baldrige Executive Fellow through the National Institute of Standards and Technology (NIST). Dr. Erling also oversaw a partnership between Penrose-St. Francis Health and the University of Colorado, Colorado Springs through the William J. Hybl Sports Medicine and Performance Center, a first-of-its-kind facility, designed with intentional collaboration spaces for student and faculty education and research that opened in 2020. Prior to joining Centura Health, Dr. Erling served as President of the Alliance Group, a subsidiary of Envision Healthcare. He was also a founding partner of the Apex Emergency Group, PC in Denver and has served as the Denver medical director for American Medical Response. Dr. Erling received his Bachelor of Science in biology from Drake University in Des Moines, Iowa; his Medical Doctorate from Johns Hopkins University in Baltimore; and his Master of Business Administration from the University of Colorado in Denver. He completed his residency in emergency medicine at the University of Virginia in Charlottesville. Dr. Erling is board certified through the American Board of Emergency Medicine. “Dr. Erling is a collaborative and relational leader who brings a depth of experience to Renown Health and to our community. He is a healthcare executive focused on clinical quality and safety, an approachable servant-leader who inspires others with emotional intelligence and relationship skills; and a seasoned strategist with experience and discipline around healthcare operations, finance, and a proven ability to advance performance,” said Adam Kramer, chair of Renown Health’s Board of Directors. “Dr. Erling has the exceptional leadership skills, experience, background, vision and a commitment to Renown’s mission, values, and culture. We are happy to have Dr. Erling leading Renown Health and know he, his wife Jessica and family will be warmly welcomed to our northern Nevada community.” “I am so excited to be joining Renown Health at this important time. Healthcare and our economy are in the midst of a major transformation, and Renown Health is very well positioned for the future,” Dr. Erling said. “Our ongoing success will hinge on our ability to establish positive and productive relationships, maintain high-quality patient clinical outcomes and experiences, reduce healthcare costs, encourage innovation and improve access and affordability for patients and members.” Dr. Erling will assume the full duties of president and CEO on November 14, 2022. Dr. Thomas Graf, who has served as interim CEO and Sy Johnson MBA, who has served as interim president, will both work with Dr. Erling to ensure a smooth transition of responsibilities. Dr. Graf will continue to serve as Chief Clinical and Quality Officer for Renown Health and Senior Associate Dean for Clinical Affairs at the University of Nevada, Reno School of Medicine. Sy Johnson, MBA, will continue to serve as Chief Operations Officer and Chief of Staff for Renown Health. Dr. Erling and his wife Jessica have three adult children and enjoy making the most of the great outdoors. About Renown Health Renown Health is Nevada’s largest, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe, and northeast California. With a diverse workforce of more than 6,500 employees, Renown has fostered a longstanding culture of excellence, determination, and innovation. The organization comprises a trauma center, two acute care hospitals, a children’s hospital, a rehabilitation hospital, a medical group and urgent care network, and the locally owned not-for-profit insurance company, Hometown Health. Renown is currently enrolling participants in a community-based genetic population health study, the Healthy Nevada Project®.

Read More About Brian Erling, MD, MBA, Named President & CEO Of Renown Health

Gilead Sciences, Inc. (Nasdaq: GILD) and the Renown Institute for Health Innovation (IHI) today announced a strategic collaboration to collect and analyze genetic and electronic health data that can enhance the understanding of nonalcoholic steatohepatitis (NASH) and potentially inform development of treatment options for the disease. Under the terms of the collaboration and license agreement, Gilead will provide funding to Renown IHI to sequence and analyze the DNA of 15,000 individuals living with NASH or nonalcoholic fatty liver disease (NAFLD) as well as a control cohort of 40,000 individuals in Nevada. “Combining the sequencing of protein coding DNA, with extensive electronic health record data will enable a deep analysis of the roles of genetics and environment in NASH incidence and progression,” said John McHutchison, AO, MD, Chief Scientific Officer and Head of Research and Development, Gilead Sciences. “The analysis of these large datasets in collaboration with Renown IHI could help identify genetic variants that impact the risk of developing NASH and thereby advance the discovery and development of new treatments for this disease.” Renown Health is Nevada’s most comprehensive and integrated healthcare network and maintains electronic health records for 1.02 million registered patients. In 2016, Renown Health and the Desert Research Institute established the Healthy Nevada Project (HNP), the nation’s first community-based population health study. In 2017 HNP began a partnership with Helix to leverage its population health services, Exome+™ sequencing, and consumer engagement tools. The HNP is now an ongoing collaboration between Renown IHI, the Desert Research Institute, a global leader in environmental data and applied research, and Helix, a personal genomics company. HNP combines genetic, environmental, social and clinical data to address individual and community health needs with the goal of improving health across the state and the nation. The HNP currently has 40,000 participants. “Combining genetic sequencing with large sets of data can play a critical role in understanding and identifying serious health risks, including diseases like NASH. We are excited to collaborate with Gilead to better understand the condition and its complexities,” said Anthony Slonim, MD., DrPH. “Any genetic variants identified in participants through the collaboration may be shared with the participants for patient care purposes.”     About NASH Nonalcoholic steatohepatitis (NASH) is a chronic form of liver disease characterized by excess fat in the liver, inflammation, and liver cell damage. Inflammation and liver cell damage can cause scarring of the liver, or fibrosis, and ultimately lead to cirrhosis or liver cancer. NASH is more common in people with certain conditions, including obesity and type 2 diabetes. There are currently limited approved treatments for patients living with NASH.   About Gilead Sciences Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California. For more information on Gilead Sciences, please visit the company’s website at www.gilead.com.   About Renown Health Renown Health is a locally governed and locally owned, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. Renown is one of the region’s largest private employers with a workforce of more than 7,000. It comprises three acute care hospitals, a rehabilitation hospital, the area’s most comprehensive medical group and urgent care network, and the region’s largest and only locally owned not-for-profit insurance company, Hometown Health. Renown Health’s commitment has extended beyond traditional health care to include community health and well-being. Renown Health works to improve health care through science, research and genetics; forge community partnerships that improve lives and develop innovative models that are improving health care in Nevada. For more information, visit renown.org.    About Helix Helix’s mission is to empower every person to improve their life through DNA. Helix is accelerating the integration of genomic data into clinical care and broadening the impact of large-scale population health programs by providing comprehensive expertise in DNA sequencing, bioinformatics, and individual engagement. Powered by their proprietary Exome+™ assay—a panel-grade exome enhanced by more than 300,000 informative non-coding regions—Helix offers health systems a scalable solution which enables the discovery of medically relevant, potentially life-saving, genetic information. Additionally, Helix offers a suite of DNA-powered products for continued individual engagement and discovery. Helix is headquartered in the San Francisco Bay Area and has one of the world’s largest CLIA-certified, CAP-accredited Next Generation Sequencing labs, located in San Diego, California. Learn more at www.helix.com. Helix, the Helix logo, and Exome+ are trademarks of Helix Opco, LLC.   Gilead Forward-Looking Statement This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the risk that the parties may not realize the potential benefits of this collaboration, and Gilead may fail to discover, develop and commercialize any product candidates for the treatment of NASH. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2019, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements. For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.   Additional Media Contact: Sung Lee, Investors                                                                                                                                                        650-524-7792 Arran Attridge, Media                                                                                                                                                        650-425-8975

Read More About Gilead Sciences and Renown Institute for Health Innovation Announce Strategic Collaboration to Advance Understanding of Nonalcoholic Steatohepatitis (NASH)

Get to know Renown’s new CEO in his letter to employees and care providers. Today marks Dr. Brian Erling’s first day as Renown Health’s President & CEO. Dr. Erling sent the following letter and this video to Renown’s employees and care providers. We are pleased to share it with our community. Hello! Today marks my first day as your Renown Health President and CEO, so I thought I would kick off the occasion with a note. Throughout the interview process, I have been beyond impressed with the passion and purpose demonstrated by all who I have met, and I am overwhelmed with gratitude for the warm welcome that we have received. I look forward to meeting each and every one of you, but it may take some time to get to all 7000 of you, so I thought I would share some information not included in the initial announcement. A bit about where I come from and what I believe, which informs how I approach leadership. Healthcare has been my passion for as long as I can remember. I grew up in Minnesota and started my healthcare career as a nursing assistant during high school, and then as a monitor tech during college. After medical school and training, I went on to spend the next dozen years in the ED of a Level I trauma center in west Denver. I met my wife, Jessica, while attending medical school in Baltimore. She was working as a nurse in the surgical ICU and I was smitten. I offered to help her with a 3 am turn and bed linen change for our trauma patient, and the rest was history. We have three kids ages 17-22. I may wear a suit, but first and foremost I am a husband, father, clinician and a caregiver. Over the last 20+ years, I have worked my fair share of nights, weekends, and holidays, and I know the sacrifice you and your families make to care for our community. I will never take it for granted. I have been the sole provider covering a busy night shift, and I know that the trust and collaboration with your immediate team matters more than anything I am putting in this email. In fact, being part of a high performing, mission-driven team is my number one motivation. It’s what gets me up in the morning and why I work in healthcare. I have provided clinical leadership for a large, regional health system and understand that quality, safety, and innovation comes from the people doing the work, not from a corporate office. But you also need strong managers and leaders to facilitate and prioritize the work, and to provide support and inspiration. I view our greatest resource to be our people (each of you). Fancy robots, imaging equipment, etc. are essential, but they are not why our patients choose us. They come for your brand of hometown, trusted care. I am very excited about the new partnership with Renown and the University of Nevada, Reno School of Medicine. While still in its infancy, it provides the platform for us to be the center for training, research, and tertiary care for the region (and beyond). Most health systems would love to have their own health plan. The reality is that you cannot meaningfully improve the health of the population without managing value and risk. We are fortunate to have Hometown Health as part of Renown Health, and in our community, and I am excited to work with them to fulfill the mission of the organization. I have worked in for-profit and not-for profit healthcare. Renown is unique in the market as the only nonprofit health system in the market. What that means is that we invest every penny earned back into caring for our community. We don’t send money to shareholders in California or Pennsylvania, we invest it right here in Nevada. That is the kind of organization that I want to work for and where I want my family to get care. Some of you may have noticed that healthcare leaders have an impressively short half-life. I recall not being terribly impressed with one of our hospital leaders early in my career, and one of my senior partners told me to “just wait, he’ll be gone in a year or two.” She was correct. In fact, I had five CEOs in the time I was practicing in Denver. It’s difficult to create and move an organization toward a unified vision when your leader changes every few years. As my track record will support, this is not my style. I have been in Colorado for over twenty years and now look forward to making Reno and Renown my home for years to come. We are in an unprecedented time in healthcare, as all U.S. health systems are experiencing skyrocketing expenses and insufficient revenue growth. Renown is not immune to these pressures, but we are well positioned in the market to weather the storm. By focusing on continuous clinical and operational improvement, Renown will continue to set the gold standard for community health system performance. I appreciate you taking the time to read this message. I look forward to meeting with and learning from all of you. When you see me in the hallway or out and about, please come up and say hello. The work we do is hard, but I try to make it fun when I can, and I definitely like to play hard outside of work. I have been snowboarding the Rockies for the last 20 years and am excited to ride some new trails. When I see you around, let me know if you have some favorite terrain to recommend. Here, at your side, and ready to FIGHT THE GOOD FIGHT! Brian Erling, MD, MBA President & CEO, Renown Health About Renown Health Renown Health is Nevada’s largest, locally governed, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. With a diverse workforce of more than 7,000 employees, Renown has fostered a longstanding culture of excellence, determination and innovation. The organization comprises a trauma center, two acute care hospitals, a children’s hospital, a rehabilitation hospital, a medical group and urgent care network, and the locally owned not-for-profit insurance company, Hometown Health. Renown is currently enrolling participants in the world’s largest community-based genetic population health study, the Healthy Nevada Project®.

Read More About New CEO of Renown Health, Dr. Brian Erling, Shares Thoughts With Physicians And Colleagues on His First Day

Released in partnership with the Desert Research Institute: New research from the Healthy Nevada Project® finds that a confirmed diagnosis does not always result in changes to patient care. Presenting individuals with potentially life-altering health information doesn’t mean the individuals – or their healthcare providers – will act on it. Follow-up education and conversations about actionable care plans with patients and their doctors are key next steps, according to new research from the Healthy Nevada Project.  The Healthy Nevada Project is a genetic screening and research project that launched in 2016 as a partnership between DRI and Renown Health. The project now has more than 50,000 participants, with genetic sequencing provided by Helix.  Between September 2018 and September 2020, the Healthy Nevada Project successfully notified 293 participants that they were genetically at risk for hereditary breast and ovarian cancer syndrome, Lynch syndrome, or familial hypercholesterolemia – three common genetic conditions known collectively as the Centers for Disease Control and Prevention (CDC) Tier 1 conditions. In a study published today in Frontiers in Genetics, Healthy Nevada Project scientists looked at the impact that notifying a patient of a positive finding for a CDC Tier 1 condition had on the care that the patient received in the months and years that followed.  According to their results, among the 293 Healthy Nevada Project participants who were notified of their genetic risk of a CDC Tier 1 condition, 71 percent of participants with electronic health records shared their findings with healthcare providers. However, only 30 percent of the electronic health records for these patients contained documentation of the genetic diagnosis, and only 10 percent of examined patients experienced a possible change in care after receiving the results of their genetic screening.  “The Healthy Nevada Project was implemented with a ‘hands-off’ approach where the participants receive their findings and decide with whom and when to share those findings. The findings were not automatically added to their electronic health records,” said Dr. Gai Elhanan, health data scientist at DRI and co-lead author of the study. “What we’re learning now is that to ensure that important genetic findings are integrated into the care journey it is important to make their inclusion into the electronic health records part of the study.” This study builds on previous Healthy Nevada Project research published in Nature Medicine demonstrating the importance of screening for CDC Tier 1 conditions, which affect about one in 75 individuals and can be mitigated or even prevented from developing into disease when detected early. This study found that as many as 90 percent of the CDC Tier 1 cases are missed by clinical providers during normal clinical care screenings and examinations. During the current study, the Healthy Nevada Project scientists found that 19 percent of studied participants had already developed one of the CDC Tier 1 conditions, and thus would have potentially benefited from earlier notification about their condition. The study team hopes that their findings will encourage individuals in Nevada to obtain genetic testing for these relatively common conditions. Even if individuals are older or have already suffered from diseases related to these conditions, testing could also prove beneficial to siblings, children, and grandchildren who may also be at risk and who could subsequently be screened in the event of a positive finding. The study team also encourages informing health care providers of the importance of incorporating genetic diagnoses into the pharmaceutical (for example, for Familial Hypercholesterolemia) and treatment advice given to patients.  “As a result of this analysis, the clinicians at Renown Health and the Healthy Nevada Project researchers have made significant changes, including obtaining informed consent from participants to report positive findings from their genetics reports directly into their electronic medical record,” said Daniel Kiser, M.S., assistant research scientist of data science at DRI and co-lead author of the study. “This will help both participants, their clinical providers, and the whole state maximize the long-term benefits of the Healthy Nevada Project voluntary population-based genetic screening.” Additional information: The full text of the study,  Incomplete Penetrance of Population-Based Genetic Screening Results in Electronic Health Record, is available from Frontiers in Genetics: https://www.frontiersin.org/articles/10.3389/fgene.2022.866169/full?&utm_source=Email_to_authors_&utm_medium=Email&utm_content=T1_11.5e1_author&utm_campaign=Email_publication&field=&journalName=Frontiers_in_Genetics&id=866169.  This project was funded by Renown Health, the Renown Health Foundation, and the Nevada Governor’s Office of Economic Development. Study authors included Gai Elhanan (DRI), Daniel Kiser (DRI), Iva Neveux (DRI), Shaun Dabe (Renown Health), Alexander Bolze (Helix), William Metcalf (DRI), James Lu (Helix), and Joseph Grzymski (DRI/Renown Health). For more information on the Healthy Nevada Project® or to request genetic screening, please visit: https://healthynv.org/ About DRI The Desert Research Institute (DRI) is a recognized world leader in basic and applied environmental research. Committed to scientific excellence and integrity, DRI faculty, students who work alongside them, and staff have developed scientific knowledge and innovative technologies in research projects around the globe. Since 1959, DRI’s research has advanced scientific knowledge on topics ranging from humans’ impact on the environment to the environment’s impact on humans. DRI’s impactful science and inspiring solutions support Nevada’s diverse economy, provide science-based educational opportunities, and inform policymakers, business leaders, and community members. With campuses in Las Vegas and Reno, DRI serves as the non-profit research arm of the Nevada System of Higher Education. For more information, please visit www.dri.edu. About Renown Health Renown Health is the region’s largest, locally governed, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. With a diverse workforce of more than 7,000 employees, Renown has fostered a longstanding culture of excellence, determination and innovation. The organization comprises a trauma center, two acute care hospitals, a children’s hospital, a rehabilitation hospital, a medical group and urgent care network, and the region’s largest, locally owned not-for-profit insurance company, Hometown Health. Renown is currently enrolling participants in the world’s largest community-based genetic population health study, the Healthy Nevada Project®. For more information, visit renown.org. About Helix Helix is the leading population genomics and viral surveillance company operating at the intersection of clinical care, research, and data analytics. Helix enables health systems, life sciences companies, payers, and government partners to accelerate the integration of genomic data into patient care and public health decision making. Learn more at www.helix.com.

Read More About Study Shows Importance of Ensuring Participant and Provider Follow-up After a Genetic Screening Result

Together, will test over 30,000 qualifying study participants by 2023 for risk of cirrhosis and liver-related illnesses. Renown Institute for Health Innovation (IHI) announced today that the organization and Gilead Sciences, Inc. will be joining forces with Siemens Healthineers to offer the Enhanced Liver Fibrosis (ELF™) Test to people with risks for nonalcoholic steatohepatitis (NASH) enrolled in the Healthy Nevada Project (HNP). The ELF Test will help identify people most at risk for progressing to cirrhosis and liver-related outcomes and allow healthcare providers to intervene before irreparable damage occurs. This noninvasive blood test uses three serum biomarkers to create an ELF score from a predefined algorithm, which can be used by doctors to help evaluate if a patient requires increased medical care and monitoring for their condition. Nonalcoholic fatty liver disease (NAFLD), which includes NASH, is prevalent in Nevada and under-diagnosed, likely affecting more than 500,000 adult Nevadans. If undetected and untreated, NASH can result in liver cirrhosis and may require liver transplantation or lead to death. There are more than 12,000 people on a waitlist for liver transplantation in the U.S. and this number continues to rise due to the increasing prevalence of NAFLD. “Thanks to important data collected through our Nonalcoholic Steatohepatitis Liver Disease Genome Atlas study, we now know that NASH is prevalent in the state of Nevada,” said Tony Slonim, M.D., DrPH, FACHE, president and CEO of Renown Health. “We are proud to expand our partnership with Gilead and begin working with Siemens Healthineers to improve health of those with liver disease and to take early detection one step further by offering Enhanced Liver Fibrosis, ELF testing for patients of Renown Health. This test provides our team of highly-skilled physicians an advanced, noninvasive method to actively assess dynamic liver fibrosis in study participants and intervene whenever necessary, contributing to a healthier Nevada.”  “Gilead believes that noninvasive tests, including the ELF Test, will help improve the experience of people living with NASH. These tests may help to diagnose liver disease, monitor disease progression and evaluate responses to treatment without the requirement for liver biopsy,” said Rob Myers, MD, Vice President, Liver Fibrosis Clinical Research at Gilead Sciences. “The ELF Test has proven itself to be a valuable tool in NASH management and we hope this partnership will further support its use in routine care.”  “We are very pleased that NASH patients in the Healthy Nevada Project now have access to the ELF Test which offers clinically useful prognostic information for their condition with the convenience of a simple blood test. Using our advanced laboratory expertise together with Renown IHI and Gilead, we can work towards better understanding of NASH and liver disease in a representative patient population,” said Sebastian Kronmueller, Head of Molecular Diagnostics at Siemens Healthineers. “We launched the Healthy Nevada Project to help people understand more about their health, to identify serious health risks, and to give people access to innovations like the ELF Test, so they can live their best lives,” said Renown’s chief scientific officer, Dr. Joseph Grzymski, who is also a research professor at the Desert Research Institute and principal investigator of the Healthy Nevada Project. It’s incredibly rewarding to be able to report clinical findings to help our 50,000 volunteer study participants, and to assist healthcare providers in helping their patients.” The provision of the ELF Test builds on a previously announced strategic collaboration between the Renown IHI and Gilead in July 2019. This ongoing partnership aims to collect and analyze de-identified genetic and electronic health data from 60,000 qualifying study participants to enhance the understanding of NAFLD and NASH and to potentially inform development of treatment options for these diseases.  About NAFLD and NASH NAFLD is a build-up of fat in the liver of people who do not have a history of alcohol misuse. It is normal for the liver to contain some fat, but if more than 5 percent of the liver content is fat, it’s considered a fatty liver (steatosis). NASH is the most severe form of NAFLD in which a person has liver cell damage and inflammation of the liver. Inflammation and liver cell damage can cause fibrosis, or scarring of the liver, and can cause decreased liver function (1). The symptoms of NASH are often silent or non-specific, making it difficult to diagnose. About one-third of people with NASH develop cirrhosis or irreversible liver damage (2). About the ELF™ Test The ELF Test is a noninvasive blood test that can quickly identify which patients are at an elevated risk for developing cirrhosis and other liver-related clinical events (LREs). In contrast to standard liver enzyme tests that reflect liver damage that has already occurred, the ELF Test combines three serum direct biomarkers of active fibrosis. The ELF Test algorithm measures each of these biomarkers to create an ELF score, which can be used as an aid to assess the risk for future disease progression. Doctors may use this ELF score to help evaluate if a patient requires increased medical care and monitoring for their condition. Individuals interested in determining their risk for NASH and its progression are encouraged to enroll in the Nonalcoholic Steatohepatitis Liver Disease Genome Atlas study. Those who have already consented and participated in the study will be contacted with more information on how to receive an ELF blood test. For more information or to enroll, please contact RenownIHI@renown.org or (775) 982-6914. The Enhanced Liver Fibrosis (ELF™) Test kit is not available for sale in the U.S. Product availability may vary from country to country and is subject to varying regulatory requirements.  In the U.S., the ELF Testing Service is available from Siemens Healthcare Laboratory, LLC (SHL), a CLIA-certified laboratory located in Berkeley, Calif. The ELF Testing Service, including the establishment of performance characteristics, was developed by SHL. The ELF Test has not been cleared or approved by the U.S. Food and Drug Administration. SHL is regulated under CLIA as qualified to perform high complexity testing. The ELF Test is used for clinical purposes and should not be regarded as investigational use only or research use only. About Renown Health Renown Health is the region’s largest, locally owned and governed, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. With a diverse workforce of more than 7,000 employees, Renown has fostered a longstanding culture of excellence, determination and innovation. The organization comprises a trauma center, two acute care hospitals, a children’s hospital, a rehabilitation hospital, a medical group and urgent care network, and the region’s largest, locally owned not-for-profit insurance company, Hometown Health. Renown’s institute model addresses social determinants of health and includes: Child Health, Behavioral Health & Addiction, Healthy Aging and Health Innovation. Clinical institutes include: Cancer, Heart and Vascular Health, Neurosciences and Robotic Surgery. Renown is currently enrolling participants in the world’s largest community-based genetic population health study, the Healthy Nevada Project®. For more information visit, renown.org. About the Renown Institute for Health Innovation Renown Institute for Health Innovation is a collaboration between Renown Health - a locally governed and locally owned, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California; and the Desert Research Institute - a recognized world leader in investigating the effects of natural and human-induced environmental change and advancing technologies aimed at assessing a changing planet. Renown IHI research teams are focused on integrating personal healthcare and environmental data with socioeconomic determinants to help Nevada address some of its most complex environmental health problems; while simultaneously expanding the state’s access to leading-edge clinical trials and fostering new connections with biotechnology and pharmaceutical companies. Learn more at healthynv.org. Renown Health is Nevada’s most comprehensive and integrated healthcare network and maintains electronic health records for 1.02 million registered patients. In 2016, Renown Health and the Desert Research Institute established the Healthy Nevada Project (HNP), the nation’s first community-based population health study. In 2017 HNP began a partnership with Helix to leverage its population health services, Exome+™ sequencing, and consumer engagement tools. The HNP is now an ongoing collaboration between Renown IHI, the Desert Research Institute, a global leader in environmental data and applied research, and Helix, a personal genomics company. HNP combines genetic, environmental, social and clinical data to address individual and community health needs with the goal of improving health across the state and the nation. The HNP currently has over 60,000 participants. For more information, visit healthynv.org.  About Siemens Healthineers Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) is shaping the future of Healthcare. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers enables healthcare providers worldwide through its regional companies to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving the patient experience, and digitalizing healthcare. Siemens Healthineers is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company’s foundation in in-vitro diagnostic, image-guided therapy, and in-vivo diagnostics. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers ability to provide high-quality, efficient care to patients. In fiscal 2020, which ended on September 30, 2020, Siemens Healthineers, which has approximately 54,000 employees worldwide, generated revenue of €14.5 billion and adjusted EBIT of €2.2 billion. Further information is available at www.siemens-healthineers.com.Media Contact for Siemens Healthineers: Lance LongwellM: 610-448-6341E: lance.longwell@siemens-healthineers.com

Read More About Renown Institute Expands Partnership to Offer ELF Testing